26304 Efficacy and safety of crisaborole in patients with mild-to-moderate atopic dermatitis with and without comorbid allergies or asthma
Peter Lio(Northwestern University), Liza Takiya(Pfizer (United States)), Chuanbo Zang(Pfizer (United States)), Michael S. Blaiss(Augusta University), Aharon Kessel(Technion – Israel Institute of Technology), Michael A. O’Connell(Pfizer (United States)), Wendy C. Cantrell(Children’s Village), Michael J. Cork(Royal Hallamshire Hospital), John L. Werth(Pfizer (United States)), Jonathan M. Spergel(University of Pennsylvania)
Cited by 1
Related Papers
Eosinophilic esophagitis: Updated consensus recommendations for children and adults
|Journal of Allergy and Clinical Immunology|2011|2.1k
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
|New England Journal of Medicine|2016|2k
The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria
|Allergy|2021|1.2k